We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Chemomab Therapeutics Ltd | NASDAQ:CMMB | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 3.70% | 0.84 | 0.8001 | 1.07 | 0.845 | 0.7603 | 0.79 | 69,651 | 05:00:02 |
Exhibit
|
Description
|
|
CHEMOMAB THERAPEUTICS LTD.
|
|
|
|
|
Date: March 7, 2024
|
By:
|
/s/ Sigal Fattal
|
|
|
Sigal Fattal
|
|
|
Chief Financial Officer
|
• |
In January, 2024, Chemomab reported publication of new proteomics research in the peer-reviewed journal Cells reinforcing the clinical potential of CM-101 in primary sclerosing cholangitis.
|
• |
In January, 2024, Chemomab announced early completion of patient enrollment in the CM-101 Phase 2 PSC SPRING trial and moved up the expected topline data readout to
midyear 2024.
|
• |
In November, 2023, Chemomab presented new data at ACR Convergence 2023 further confirming that its CCL24 target is a major driver of the fibrotic and inflammatory
processes underlying systemic sclerosis (SSc) and other fibro-inflammatory diseases.
|
• |
In November, 2023, Chemomab announced that CM-101 had received FDA Fast Track designation for the treatment of PSC in adult patients.
|
• |
In November, 2023, at AASLD's The Liver Meeting® 2023, Chemomab hosted several presentations. An oral presentation of new proteomic patient data highlighted the unique
association of the company’s CCL24 target with key PSC pathways and provided further evidence that CM-101 ameliorates these damaging effects.
|
• |
In June, 2023, Chemomab announced a new publication in the peer-reviewed journal JCI Insight demonstrating the key role of CCL24 in PSC and presenting data showing how CM-101 interrupts the fibro-inflammatory processes underlying the disease.
|
• |
In June, 2023, at the 2023 EASL Congress, Chemomab hosted a late-breaking presentation reporting new positive data from its CM-101 Phase 2a liver fibrosis trial.
|
• |
In June, 2023, Chemomab announced that Adi Mor, PhD, had been reappointed to the role of Chief Executive Officer. Sigal Fattal was reappointed as Chief Financial
Officer. Nissim Darvish, MD, PhD, was appointed Chairman of the Board. The company also announced that it was implementing cost-reduction measures that extended its cash runway to the end of 2024.
|
• |
In June, 2023, Chemomab presented patient data at the 2023 EULAR Congress showing that serum CCL24 levels can predict the vascular and fibrotic complications of
systemic sclerosis.
|
• |
In May, 2023, Chemomab presented data at the 2023 EASL Biliary Conference reinforcing the pro-inflammatory role of CCL24 in PSC and other cholestatic diseases.
|
• |
In February, 2023, Chemomab received FDA IND clearance for a CM-101 Phase 2 trial in SSc patients. Chemomab has not yet initiated patient enrollment in this trial.
|
• |
In January, 2023, Chemomab reported topline results from its Phase 2a Liver
Fibrosis trial in NASH patients demonstrating that CM-101 met its primary endpoint of safety and tolerability and showed positive activity across multiple liver fibrosis biomarkers and physiologic assessments.
|
• |
Cash Position: Cash, cash equivalents and short-term bank
deposits were $19.9 million as of December 31, 2023 compared to $39.9 million as of December 31, 2022.
|
• |
Research and Development (R&D) Expenses: R&D expenses were $3.1 million for the fourth quarter and $18.4 million for the full year ended December 31, 2023, compared to $5.9 million and $17.0 million for the
respective periods in 2022. The decrease in R&D expenses in the fourth quarter of 2023 compared to the fourth quarter of 2022 figure primarily resulted from the early completion of patient enrollment in the company’s CM-101 Phase 2 PSC
trial.
|
• |
General and Administrative (G&A) Expenses: G&A expenses
were $0.8 million for the fourth quarter and $7.1 million for the full year ended December 31, 2023, compared to $2.7 million and $11.6 million for the fourth quarter and full year in 2022. The decrease in G&A expenses reflected selected
reductions in headcount, and reductions in share-based payments and recruitment costs.
|
• |
Net Loss: Net loss was $3.4 million, or a net loss of $0.01 per
basic and diluted Ordinary Share, for the fourth quarter and $24.2 million, or a net loss of $0.10 per basic and diluted Ordinary Share for the year ended December 31, 2023, compared to a net loss of $8.3 million, or a net loss of $0.04 per
basic and diluted share, for the fourth quarter of 2022 and $27.6 million, or a net loss of $0.12 per basic and diluted Ordinary Share, for the full year ended December 31, 2022.
|
December 31,
|
December 31,
|
|||||||
2023
|
2022
|
|||||||
Assets
|
Unaudited
|
Audited
|
||||||
Current assets
|
||||||||
Cash and cash equivalents
|
9,292
|
13,519
|
||||||
Short-term bank deposit
|
10,492
|
26,374
|
||||||
Restricted cash
|
76
|
77
|
||||||
Other receivables and prepaid expenses
|
1,037
|
1,766
|
||||||
Total current assets
|
20,897
|
41,736
|
||||||
Non-current assets
|
||||||||
Long-term prepaid expenses
|
559
|
733
|
||||||
Property and equipment, net
|
303
|
367
|
||||||
Operating lease right-of-use assets
|
392
|
227
|
||||||
Total non-current assets
|
1,254
|
1,327
|
||||||
Total assets
|
22,151
|
43,063
|
||||||
Current liabilities
|
||||||||
Trade payables
|
516
|
1,688
|
||||||
Accrued expenses
|
3,423
|
3,378
|
||||||
Employee and related expenses
|
825
|
1,560
|
||||||
Operating lease liabilities
|
76
|
123
|
||||||
Total current liabilities
|
4,840
|
6,749
|
||||||
Non-current liabilities
|
||||||||
Non-current operating
lease liabilities
|
316
|
91
|
||||||
Total non-current liabilities
|
316
|
91
|
||||||
Commitments and contingent liabilities
|
||||||||
Total liabilities
|
5,156
|
6,840
|
||||||
Shareholders' equity (*)
|
||||||||
Ordinary Shares no par value - Authorized: 650,000,000 Ordinary Shares as of December 31, 2023 and 2022;
|
||||||||
Issued and outstanding: 284,094,700 Ordinary shares at December 31, 2023 and 232,636,700 Ordinary shares at December 31, 2022
|
-
|
-
|
||||||
Treasury share at cost (11,640,460 shares as of December 31, 2022)
|
-
|
(1,218
|
)
|
|||||
Additional paid-in capital
|
105,675
|
101,260
|
||||||
Accumulated deficit
|
(88,680
|
)
|
(63,819
|
)
|
||||
Total shareholders’ equity
|
16,995
|
36,223
|
||||||
Total liabilities and shareholders’ equity
|
21,151
|
43,063
|
Three months
|
Three months
|
Year
|
Year
|
|||||||||||||
Ended
|
Ended
|
Ended
|
Ended
|
|||||||||||||
December 31,
|
December 31,
|
December 31,
|
December 31,
|
|||||||||||||
2023
|
2022
|
2023
|
2022
|
|||||||||||||
Unaudited
|
Unaudited
|
Unaudited
|
Audited
|
|||||||||||||
Operating expenses
|
||||||||||||||||
Research and development
|
3,097
|
5,895
|
18,381
|
16,977
|
||||||||||||
General and administrative
|
751
|
2,747
|
7,078
|
11,556
|
||||||||||||
Total operating expenses
|
3,848
|
8,642
|
25,459
|
28,533
|
||||||||||||
Financing income, net
|
(431
|
)
|
(380
|
)
|
(1,238
|
)
|
(353
|
)
|
||||||||
Loss before taxes
|
3,417
|
8,262
|
24,221
|
28,180
|
Taxes on income (Benefit)
|
-
|
10
|
-
|
(534
|
)
|
|||||||||||
Net loss
|
3,417
|
8,272
|
24,221
|
27,646
|
Basic and diluted loss per Ordinary Share*
|
0.013
|
0.036
|
0.103
|
0.121
|
Weighted average number of Ordinary Shares outstanding, basic, and diluted*
|
260,274,470
|
230,966,824
|
234,998,859
|
227,589,288
|
1 Year Chemomab Therapeutics Chart |
1 Month Chemomab Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions